Stock Ratings | With potential gains of up to 2300%, HC Wainwright & Co. maintains a "buy" rating on Enlivex (ENLV) stock, raising its price target from $13 to $20.
Enlivex ENLV | 0.00 | |
FuboTV FUBO | 0.00 | |
Neurocrine Biosciences, Inc. NBIX | 0.00 | |
Equillium EQ | 0.00 | |
Cadrenal Therapeutics, Inc. CVKD | 0.00 |
The ratings of major US investment banks are used to track the latest valuations and target prices on Wall Street daily, and to explore potential equity investment opportunities.
Risk warning:
Investing in small-cap stocks can be risky. Be prepared for potential challenges related to liquidity, high volatility, limited information, and financial instability. Always diversify your investments.
Today's key assessments and concerns
HC Wainwright & Co.: Maintaining a "buy" rating on Enlivex ( Enlivex(ENLV.US) ), with a price target raised from $13 to $20.
Wedbush: Maintaining FuboTV's ( FuboTV(FUBO.US) ) rating at "Outperforming the Market," while raising its price target from $3.50 to $24.
Citigroup: Maintaining a "buy" rating on Neurocrine Biosciences Neurocrine Biosciences, Inc.(NBIX.US) , while raising the price target from $204 to $242.
Cantor Fitzgerald: Initial rating for Equillium ( Equillium(EQ.US) ) at "overweight", with a price target of $10.
HC Wainwright & Co.: Maintaining a "buy" rating on Cadrenal Therapeutics ( Cadrenal Therapeutics, Inc.(CVKD.US) ), while lowering the price target from $32 to $13.
| The symbol | Classification | Target price | Current price | Percentage of potential increase/decrease | (Classification) Agency |
| Enlivex(ENLV.US) | to lift | $20.0 | $0.8334 | 2299.81% | HC Wainwright & Co. |
| FuboTV(FUBO.US) | to lift | $24.0 | $12.46 | 92.62% | Wedbush |
| Neurocrine Biosciences, Inc.(NBIX.US) | to lift | $242.0 | $130.9 | 84.87% | Citigroup |
| Denali Therapeutics Inc.(DNLI.US) | to lift | $34.0 | $19.41 | 75.17% | Baird |
| Neurocrine Biosciences, Inc.(NBIX.US) | to lift | $215.0 | $130.9 | 64.25% | HC Wainwright & Co. |
| Equillium(EQ.US) | Initial classification | $10.0 | $1.92 | 420.83% | Cantor Fitzgerald |
| Cadrenal Therapeutics, Inc.(CVKD.US) | cut | $13.0 | $4.32 | 200.93% | HC Wainwright & Co. |
| Viridian Therapeutics, Inc.(VRDN.US) | cut | $31.0 | $13.96 | 122.06% | Goldman Sachs |
| Viridian Therapeutics, Inc.(VRDN.US) | cut | $30.0 | $13.96 | 114.9% | RBC Capital |
| Root, Inc. Class A(ROOT.US) | cut | $95.0 | $44.56 | 113.2% | Keefe, Bruyette & Woods |
comments:
Target price unit and current price: US Dollar;
Current price: As of the latest closing price of US stocks;
Potential percentage increase/potential decrease = (Agency target price - current price) / current price 100% (Current price = Last closing price up to the time of the count)
Lifting
B. Riley Securities: Maintaining a "buy" rating on Alcoa ( Alcoa Corporation(AA.US) ), with a price target raised from $78 to $96.
Barclays: Maintaining Asbury Automotive's ( Asbury Automotive Group, Inc.(ABG.US) ) rating at "Market-equal weight," while raising the price target from $230 to $235.
Keefe, Bruyette & Woods: Maintaining its rating on Arch Capital ( Arch Capital Group Ltd.(ACGL.US) ) at "Market Match," while raising its price target from $104 to $105.
Wells Fargo: Maintaining Advanced Energy Industries ( Advanced Energy Industries, Inc.(AEIS.US) ) rating at "Market-equal weight," while raising the price target from $300 to $340.
Piper Sandler: Maintaining a "neutral" rating on Akamai Technologies (AKAM) stock, while raising the price target from $97 to $114.
First Coverage
Lake Street: Initial rating for Compugen ( Compugen Ltd.(CGEN.US) ) stock at "Buy", with a target price of $6.
Cantor Fitzgerald: Initial rating for Equillium ( Equillium(EQ.US) ) at "overweight", with a price target of $10.
Benchmark: A preliminary rating of Forum Markets ( Forum Markets, Incorporated(FRMM.US) ) stock at "speculative buy", with a target price of $5.
reduction
Piper Sandler: Maintaining a "neutral" rating on Abacus Global Management ( Abacus Global Management, Inc. Class A(ABX.US) ), while lowering the price target from $11 to $9.5.
Keefe, Bruyette & Woods: Maintaining American Integrity's ( American Integrity Insurance Group, Inc.(AII.US) ) rating at "Outperform Market", while lowering the price target from $28 to $27.
Keefe, Bruyette & Woods: Maintaining Arthur J. Gallagher Arthur J. Gallagher & Co.(AJG.US) rating at "Market Match," while lowering the price target from $249 to $246.
Editor's Note: This content was created by Saham's AI-powered SaaS tool and reviewed by our editorial team.
Risk warning:
Investing involves risk, and securities prices can rise or fall, or even become worthless. Investing does not guarantee profits and may result in losses. Past performance is not necessarily indicative of future results. Before making any investment decision, investors should assess their financial situation, investment objectives, experience, and risk tolerance, and understand the nature of the investment products and their associated risks. For more details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, it is advisable to seek independent professional advice.